



Supporting information
![]() | Crystallographic Information File (CIF) https://doi.org/10.1107/S1600536811017004/dn2682sup1.cif |
![]() | Structure factor file (CIF format) https://doi.org/10.1107/S1600536811017004/dn2682Isup2.hkl |
![]() | Chemical Markup Language (CML) file https://doi.org/10.1107/S1600536811017004/dn2682Isup3.cml |
Key indicators
- Single-crystal X-ray study
- T = 298 K
- Mean
(C-C) = 0.004 Å
- R factor = 0.028
- wR factor = 0.074
- Data-to-parameter ratio = 13.2
checkCIF/PLATON results
No syntax errors found
Alert level B PLAT029_ALERT_3_B _diffrn_measured_fraction_theta_full Low ....... 0.95 PLAT430_ALERT_2_B Short Inter D...A Contact O2 .. O2 .. 2.81 Ang.
Alert level C PLAT250_ALERT_2_C Large U3/U1 Ratio for Average U(i,j) Tensor .... 2.37 PLAT431_ALERT_2_C Short Inter HL..A Contact Br1 .. O1 .. 3.13 Ang. PLAT911_ALERT_3_C Missing # FCF Refl Between THmin & STh/L= 0.600 72 PLAT912_ALERT_4_C Missing # of FCF Reflections Above STh/L= 0.600 9
0 ALERT level A = Most likely a serious problem - resolve or explain 2 ALERT level B = A potentially serious problem, consider carefully 4 ALERT level C = Check. Ensure it is not caused by an omission or oversight 0 ALERT level G = General information/check it is not something unexpected 0 ALERT type 1 CIF construction/syntax error, inconsistent or missing data 3 ALERT type 2 Indicator that the structure model may be wrong or deficient 2 ALERT type 3 Indicator that the structure quality may be low 1 ALERT type 4 Improvement, methodology, query or suggestion 0 ALERT type 5 Informative message, check
To a stirred solution of 6-bromo-1,3-dihydro-imidazo[4,5 - b-]pyridin-2-one (0.2 g; 93.4 mmol), K2CO3 (0.38 g; 2.8 mmol), and tetra n-butyl ammonium bromide (0.03 g; 9.34 10–5 mol) in DMF, acetyl chloride (0.08 ml; 1.12 mmol) was added dropwise. The mixture was heated under reflux for 24 h. After completion of reaction (monitored by TLC), the salt was filtered and the solvent was removed under reduced pressure. The resulting residue was purified by column chromatography on silica gel using (ethylacetate/hexane) (1/1) as eluent. Crystals were isolated after the solvent was allowed to evaporate.
H atoms were located in a difference map and treated as riding with C—H = 0.93 Å for all aromatic H atoms and 0.96 Å for the methyl with Uiso(H) = 1.2 Ueq and Uiso(H) = 1.5 Ueq for the aromatic and methyl respectively.
Imidazo[4,5-b]pyridines represent the major backbone of numerous medical and biochemical agents possessing different chemical and pharmacological features (Kale et al., 2009; Silverman, 2004), which impart them diverse biological properties like antiviral (Cristalli et al.,1995; Cundy et al., 1997; Banie et al., 2007), and anti-inflammatory (Mader, 2008) activity. Substituted imidazo[4,5-b]pyridines have also been tested for their potential selective antihistamine (H1) agents (Janssens et al.,1985). Imidazo[4,5-b]pyridine derivatives were also reported as Aurora kinases (Bavetsias et al., 2007) and cyclic PDE inhibitors (Coates et al.,1993). Importantly,imidazo[4,5-b]pyridine is a structural analogue of purine whose derivatives easily interact with large biomolecules such as DNA, RNA or diverse proteins in vivo.
The molecular plot of the crystal structure of 3-Acetyl-6-bromo-1,3-dihydro- imidazo[4,5-b]pyridin-2-one is shown in Fig.1. The two fused five and six-membered rings building the molecule are nearly planar with the maximum deviation from the mean plane being -0.011 (3) A ° at N2. They form a dihedral angle of 2.7 (2)° with the acetyl group. In the crystal, adjacent molecules are linked by intermolecular N—H···N and C—H···O hydrogen bonding in the way to form infinite chains as shown in Fig. 2 and Table 1.
For background information on the pharmacological activities of imidazo[4,5-b]pyridines, see: Kale et al. (2009); Silverman (2004); Cristalli et al. (1995); Cundy et al. (1997); Banie et al. (2007); Mader (2008); Janssens et al. (1985); Bavetsias et al. (2007); Coates et al. (1993).
Data collection: APEX2 (Bruker, 2009); cell refinement: SAINT (Bruker, 2009); data reduction: SAINT (Bruker, 2009); program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEPIII (Burnett & Johnson, 1996) and ORTEP-3 for Windows (Farrugia, 1997); software used to prepare material for publication: SHELXL97 (Sheldrick, 2008).
C8H6BrN3O2 | Z = 2 |
Mr = 256.07 | F(000) = 252 |
Triclinic, P1 | Dx = 1.887 Mg m−3 |
Hall symbol: -P 1 | Melting point: 507 K |
a = 4.8302 (15) Å | Mo Kα radiation, λ = 0.71073 Å |
b = 9.645 (3) Å | Cell parameters from 1685 reflections |
c = 9.809 (3) Å | θ = 2.1–26.0° |
α = 81.542 (7)° | µ = 4.53 mm−1 |
β = 85.735 (7)° | T = 298 K |
γ = 89.676 (8)° | Fiber, colourless |
V = 450.8 (2) Å3 | 0.41 × 0.16 × 0.11 mm |
Bruker APEXII CCD diffractometer | 1685 independent reflections |
Radiation source: fine-focus sealed tube | 1583 reflections with I > 2σ(I) |
Graphite monochromator | Rint = 0.019 |
φ and ω scans | θmax = 26.0°, θmin = 2.1° |
Absorption correction: multi-scan (SADABS; Bruker, 2009) | h = −5→5 |
Tmin = 0.423, Tmax = 0.607 | k = −11→11 |
2559 measured reflections | l = 0→12 |
Refinement on F2 | Primary atom site location: structure-invariant direct methods |
Least-squares matrix: full | Secondary atom site location: difference Fourier map |
R[F2 > 2σ(F2)] = 0.028 | Hydrogen site location: inferred from neighbouring sites |
wR(F2) = 0.074 | H-atom parameters constrained |
S = 1.07 | w = 1/[σ2(Fo2) + (0.0374P)2 + 0.2048P] where P = (Fo2 + 2Fc2)/3 |
1685 reflections | (Δ/σ)max = 0.001 |
128 parameters | Δρmax = 0.43 e Å−3 |
0 restraints | Δρmin = −0.48 e Å−3 |
C8H6BrN3O2 | γ = 89.676 (8)° |
Mr = 256.07 | V = 450.8 (2) Å3 |
Triclinic, P1 | Z = 2 |
a = 4.8302 (15) Å | Mo Kα radiation |
b = 9.645 (3) Å | µ = 4.53 mm−1 |
c = 9.809 (3) Å | T = 298 K |
α = 81.542 (7)° | 0.41 × 0.16 × 0.11 mm |
β = 85.735 (7)° |
Bruker APEXII CCD diffractometer | 1685 independent reflections |
Absorption correction: multi-scan (SADABS; Bruker, 2009) | 1583 reflections with I > 2σ(I) |
Tmin = 0.423, Tmax = 0.607 | Rint = 0.019 |
2559 measured reflections |
R[F2 > 2σ(F2)] = 0.028 | 0 restraints |
wR(F2) = 0.074 | H-atom parameters constrained |
S = 1.07 | Δρmax = 0.43 e Å−3 |
1685 reflections | Δρmin = −0.48 e Å−3 |
128 parameters |
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. |
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger. |
x | y | z | Uiso*/Ueq | ||
C1 | −0.0666 (6) | 0.9228 (3) | 0.7492 (3) | 0.0412 (6) | |
H1 | −0.0912 | 0.9789 | 0.6654 | 0.049* | |
C2 | 0.1373 (5) | 0.8216 (3) | 0.7536 (2) | 0.0371 (5) | |
C3 | 0.1881 (5) | 0.7340 (3) | 0.8759 (2) | 0.0377 (5) | |
H3 | 0.3253 | 0.6658 | 0.8796 | 0.045* | |
C4 | 0.0199 (5) | 0.7562 (3) | 0.9904 (2) | 0.0355 (5) | |
C5 | −0.1838 (5) | 0.8602 (3) | 0.9766 (3) | 0.0372 (5) | |
C6 | −0.2202 (6) | 0.7636 (3) | 1.2009 (3) | 0.0435 (6) | |
C7 | 0.1715 (7) | 0.5870 (3) | 1.1871 (3) | 0.0466 (6) | |
C8 | 0.1168 (8) | 0.5301 (3) | 1.3357 (3) | 0.0588 (8) | |
H8A | 0.2348 | 0.4510 | 1.3590 | 0.088* | |
H8B | −0.0740 | 0.5012 | 1.3534 | 0.088* | |
H8C | 0.1541 | 0.6013 | 1.3909 | 0.088* | |
N1 | −0.2322 (5) | 0.9436 (2) | 0.8618 (2) | 0.0426 (5) | |
N2 | −0.3244 (5) | 0.8613 (3) | 1.1034 (2) | 0.0435 (5) | |
H2 | −0.4601 | 0.9164 | 1.1191 | 0.052* | |
N3 | −0.0003 (5) | 0.6957 (2) | 1.1302 (2) | 0.0395 (5) | |
O1 | −0.2966 (5) | 0.7398 (2) | 1.3223 (2) | 0.0595 (6) | |
O2 | 0.3528 (6) | 0.5462 (3) | 1.1138 (2) | 0.0757 (8) | |
Br1 | 0.35286 (6) | 0.80290 (3) | 0.58804 (2) | 0.04632 (13) |
U11 | U22 | U33 | U12 | U13 | U23 | |
C1 | 0.0412 (14) | 0.0477 (14) | 0.0338 (13) | 0.0047 (11) | −0.0012 (10) | −0.0033 (10) |
C2 | 0.0392 (14) | 0.0439 (13) | 0.0276 (11) | −0.0007 (10) | 0.0057 (10) | −0.0072 (9) |
C3 | 0.0387 (14) | 0.0428 (12) | 0.0310 (12) | 0.0059 (10) | 0.0035 (10) | −0.0064 (10) |
C4 | 0.0369 (13) | 0.0405 (12) | 0.0283 (11) | 0.0025 (10) | 0.0032 (9) | −0.0050 (9) |
C5 | 0.0330 (13) | 0.0449 (13) | 0.0341 (12) | 0.0037 (10) | 0.0031 (10) | −0.0100 (10) |
C6 | 0.0405 (15) | 0.0523 (15) | 0.0366 (14) | 0.0057 (11) | 0.0085 (11) | −0.0088 (11) |
C7 | 0.0598 (18) | 0.0451 (14) | 0.0325 (13) | 0.0098 (12) | 0.0069 (12) | −0.0034 (10) |
C8 | 0.078 (2) | 0.0572 (17) | 0.0349 (15) | 0.0131 (15) | 0.0123 (14) | 0.0039 (12) |
N1 | 0.0397 (13) | 0.0504 (12) | 0.0371 (12) | 0.0090 (10) | −0.0002 (9) | −0.0059 (9) |
N2 | 0.0382 (12) | 0.0550 (13) | 0.0359 (12) | 0.0105 (10) | 0.0076 (9) | −0.0074 (9) |
N3 | 0.0417 (12) | 0.0461 (11) | 0.0287 (10) | 0.0075 (9) | 0.0083 (8) | −0.0045 (8) |
O1 | 0.0640 (14) | 0.0745 (14) | 0.0354 (11) | 0.0152 (11) | 0.0188 (9) | −0.0049 (9) |
O2 | 0.0976 (19) | 0.0822 (16) | 0.0386 (11) | 0.0532 (15) | 0.0185 (11) | 0.0060 (10) |
Br1 | 0.0522 (2) | 0.0565 (2) | 0.02805 (16) | 0.00477 (12) | 0.00836 (11) | −0.00472 (11) |
C1—N1 | 1.354 (3) | C6—O1 | 1.209 (3) |
C1—C2 | 1.381 (4) | C6—N2 | 1.363 (4) |
C1—H1 | 0.9300 | C6—N3 | 1.433 (3) |
C2—C3 | 1.398 (4) | C7—O2 | 1.193 (4) |
C2—Br1 | 1.894 (2) | C7—N3 | 1.409 (4) |
C3—C4 | 1.379 (3) | C7—C8 | 1.486 (4) |
C3—H3 | 0.9300 | C8—H8A | 0.9600 |
C4—C5 | 1.401 (4) | C8—H8B | 0.9600 |
C4—N3 | 1.406 (3) | C8—H8C | 0.9600 |
C5—N1 | 1.319 (3) | N2—H2 | 0.8600 |
C5—N2 | 1.374 (3) | ||
N1—C1—C2 | 122.6 (2) | N2—C6—N3 | 105.9 (2) |
N1—C1—H1 | 118.7 | O2—C7—N3 | 118.5 (2) |
C2—C1—H1 | 118.7 | O2—C7—C8 | 123.7 (3) |
C1—C2—C3 | 122.0 (2) | N3—C7—C8 | 117.8 (2) |
C1—C2—Br1 | 118.30 (19) | C7—C8—H8A | 109.5 |
C3—C2—Br1 | 119.66 (19) | C7—C8—H8B | 109.5 |
C4—C3—C2 | 115.1 (2) | H8A—C8—H8B | 109.5 |
C4—C3—H3 | 122.5 | C7—C8—H8C | 109.5 |
C2—C3—H3 | 122.5 | H8A—C8—H8C | 109.5 |
C3—C4—C5 | 119.2 (2) | H8B—C8—H8C | 109.5 |
C3—C4—N3 | 134.3 (2) | C5—N1—C1 | 115.0 (2) |
C5—C4—N3 | 106.5 (2) | C6—N2—C5 | 110.9 (2) |
N1—C5—N2 | 125.6 (2) | C6—N2—H2 | 124.6 |
N1—C5—C4 | 126.0 (2) | C5—N2—H2 | 124.6 |
N2—C5—C4 | 108.4 (2) | C4—N3—C7 | 124.2 (2) |
O1—C6—N2 | 127.0 (3) | C4—N3—C6 | 108.4 (2) |
O1—C6—N3 | 127.1 (3) | C7—N3—C6 | 127.4 (2) |
N1—C1—C2—C3 | −0.5 (5) | N1—C5—N2—C6 | −178.9 (3) |
N1—C1—C2—Br1 | 179.6 (2) | C4—C5—N2—C6 | 0.7 (3) |
C1—C2—C3—C4 | 0.1 (4) | C3—C4—N3—C7 | 0.3 (5) |
Br1—C2—C3—C4 | −179.98 (19) | C5—C4—N3—C7 | −179.4 (3) |
C2—C3—C4—C5 | 0.5 (4) | C3—C4—N3—C6 | −179.8 (3) |
C2—C3—C4—N3 | −179.2 (3) | C5—C4—N3—C6 | 0.5 (3) |
C3—C4—C5—N1 | −0.8 (4) | O2—C7—N3—C4 | 2.8 (5) |
N3—C4—C5—N1 | 178.9 (3) | C8—C7—N3—C4 | −177.5 (3) |
C3—C4—C5—N2 | 179.5 (2) | O2—C7—N3—C6 | −177.1 (3) |
N3—C4—C5—N2 | −0.7 (3) | C8—C7—N3—C6 | 2.6 (5) |
N2—C5—N1—C1 | −179.9 (3) | O1—C6—N3—C4 | −179.6 (3) |
C4—C5—N1—C1 | 0.5 (4) | N2—C6—N3—C4 | 0.0 (3) |
C2—C1—N1—C5 | 0.2 (4) | O1—C6—N3—C7 | 0.3 (5) |
O1—C6—N2—C5 | 179.1 (3) | N2—C6—N3—C7 | 179.8 (3) |
N3—C6—N2—C5 | −0.4 (3) |
D—H···A | D—H | H···A | D···A | D—H···A |
N2—H2···N1i | 0.86 | 2.02 | 2.877 (3) | 175 |
C3—H3···O2ii | 0.93 | 2.56 | 3.481 (3) | 172 |
Symmetry codes: (i) −x−1, −y+2, −z+2; (ii) −x+1, −y+1, −z+2. |
Experimental details
Crystal data | |
Chemical formula | C8H6BrN3O2 |
Mr | 256.07 |
Crystal system, space group | Triclinic, P1 |
Temperature (K) | 298 |
a, b, c (Å) | 4.8302 (15), 9.645 (3), 9.809 (3) |
α, β, γ (°) | 81.542 (7), 85.735 (7), 89.676 (8) |
V (Å3) | 450.8 (2) |
Z | 2 |
Radiation type | Mo Kα |
µ (mm−1) | 4.53 |
Crystal size (mm) | 0.41 × 0.16 × 0.11 |
Data collection | |
Diffractometer | Bruker APEXII CCD |
Absorption correction | Multi-scan (SADABS; Bruker, 2009) |
Tmin, Tmax | 0.423, 0.607 |
No. of measured, independent and observed [I > 2σ(I)] reflections | 2559, 1685, 1583 |
Rint | 0.019 |
(sin θ/λ)max (Å−1) | 0.617 |
Refinement | |
R[F2 > 2σ(F2)], wR(F2), S | 0.028, 0.074, 1.07 |
No. of reflections | 1685 |
No. of parameters | 128 |
H-atom treatment | H-atom parameters constrained |
Δρmax, Δρmin (e Å−3) | 0.43, −0.48 |
Computer programs: APEX2 (Bruker, 2009), SAINT (Bruker, 2009), SHELXS97 (Sheldrick, 2008), SHELXL97 (Sheldrick, 2008), ORTEPIII (Burnett & Johnson, 1996) and ORTEP-3 for Windows (Farrugia, 1997).
D—H···A | D—H | H···A | D···A | D—H···A |
N2—H2···N1i | 0.86 | 2.02 | 2.877 (3) | 174.5 |
C3—H3···O2ii | 0.93 | 2.56 | 3.481 (3) | 171.8 |
Symmetry codes: (i) −x−1, −y+2, −z+2; (ii) −x+1, −y+1, −z+2. |
Imidazo[4,5-b]pyridines represent the major backbone of numerous medical and biochemical agents possessing different chemical and pharmacological features (Kale et al., 2009; Silverman, 2004), which impart them diverse biological properties like antiviral (Cristalli et al.,1995; Cundy et al., 1997; Banie et al., 2007), and anti-inflammatory (Mader, 2008) activity. Substituted imidazo[4,5-b]pyridines have also been tested for their potential selective antihistamine (H1) agents (Janssens et al.,1985). Imidazo[4,5-b]pyridine derivatives were also reported as Aurora kinases (Bavetsias et al., 2007) and cyclic PDE inhibitors (Coates et al.,1993). Importantly,imidazo[4,5-b]pyridine is a structural analogue of purine whose derivatives easily interact with large biomolecules such as DNA, RNA or diverse proteins in vivo.
The molecular plot of the crystal structure of 3-Acetyl-6-bromo-1,3-dihydro- imidazo[4,5-b]pyridin-2-one is shown in Fig.1. The two fused five and six-membered rings building the molecule are nearly planar with the maximum deviation from the mean plane being -0.011 (3) A ° at N2. They form a dihedral angle of 2.7 (2)° with the acetyl group. In the crystal, adjacent molecules are linked by intermolecular N—H···N and C—H···O hydrogen bonding in the way to form infinite chains as shown in Fig. 2 and Table 1.